肿瘤微环境对大型B细胞淋巴瘤中抗CD19 CAR T细胞治疗或化疗联合移植疗效的影响
3期ZUMA-7试验显示,在二线大型B细胞淋巴瘤中,抗CD19 CAR T细胞治疗(阿基仑赛)优于标准治疗(挽救化疗后造血干细胞移植)。本预设探索性分析发现,B细胞基因表达特征和CD19表达与阿基仑赛的无事件生存改善相关,但与标准治疗无关;无论上述标志物高低,阿基仑赛均优于标准治疗。
要点
- B细胞基因表达特征和CD19表达与阿基仑赛的无事件生存改善显著相关,与标准治疗无关。
- 无论B细胞基因表达特征和CD19表达高低,阿基仑赛的无事件生存均优于标准治疗。
- 肿瘤负荷、乳酸脱氢酶和细胞起源对标准治疗的影响大于对阿基仑赛的影响。
核心结论
- 数据揭示阿基仑赛与标准治疗的耐药机制存在差异,并支持早期使用阿基仑赛。
研究设计与样本
- 3期ZUMA-7试验(NCT03391466)的预设探索性分析,纳入二线大型B细胞淋巴瘤患者,比较阿基仑赛与标准治疗(挽救化疗后造血干细胞移植)。
主要发现
- B细胞基因表达特征与阿基仑赛的无事件生存改善显著相关(P=0.0002),与标准治疗无关(P=0.9374)。
- CD19表达与阿基仑赛的无事件生存改善显著相关(P=0.0165),与标准治疗无关(P=0.5526)。
- 无论B细胞基因表达特征高低,阿基仑赛的无事件生存均优于标准治疗(高表达P=8.56×10-9;低表达P=0.0019)。
- 无论CD19基因表达高低,阿基仑赛的无事件生存均优于标准治疗(高表达P=3.85×10-9;低表达P=0.0017)。
- 肿瘤负荷、乳酸脱氢酶和细胞起源对标准治疗的影响大于对阿基仑赛的影响;T细胞活化和B细胞基因表达特征随治疗线数增加而下降。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 3 ZUMA-7 trial in second-line large B cell lymphoma demonstrated superiority of anti-CD19 CAR T cell therapy (axicabtagene ciloleucel (axi-cel)) over standard of care (SOC; salvage chemotherapy followed by hematopoietic transplantation) ( NCT03391466 ). Here, we present a prespecified exploratory analysis examining the association between pretreatment tumor characteristics and the efficacy of axi-cel versus SOC. B cell gene expression signature (GES) and CD19 expression associated significantly with improved event-free survival for axi-cel (P = 0.0002 for B cell GES; P = 0.0165 for CD19 expression) but not SOC (P = 0.9374 for B cell GES; P = 0.5526 for CD19 expression). Axi-cel showed superior event-free survival over SOC irrespective of B cell GES and CD19 expression (P = 8.56 × 10-9 for B cell GES high; P = 0.0019 for B cell GES low; P = 3.85 × 10-9 for CD19 gene high; P = 0.0017 for CD19 gene low). Low CD19 expression in malignant cells correlated with a tumor GES consisting of immune-suppressive stromal and myeloid genes, highlighting the inter-relation between malignant cell features and immune contexture substantially impacting axi-cel outcomes. Tumor burden, lactate dehydrogenase and cell-of-origin impacted SOC more than axi-cel outcomes. T cell activation and B cell GES, which are associated with improved axi-cel outcome, decreased with increasing lines of therapy. These data highlight differences in resistance mechanisms to axi-cel and SOC and support earlier intervention with axi-cel.
引用
- Locke FL, Filosto S, Chou J, et al. Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma. Nat Med. 2024. PMID: 38233586. doi:10.1038/s41591-023-02754-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。